Financials Vext Science, Inc.

Equities

VEXT

CA9255401064

Healthcare Facilities & Services

Market Closed - Canadian Securities Exchange 20:59:59 12/07/2024 BST 5-day change 1st Jan Change
0.24 CAD +4.35% Intraday chart for Vext Science, Inc. +4.35% -17.24%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 89.5 69.2 26.37 47.57 43.26 -
Enterprise Value (EV) 2 89.5 76.84 58.59 47.57 94.96 92.16
P/E ratio 39.5 x - - 7.07 x - -
Yield - - - - - -
Capitalization / Revenue 3.55 x 1.86 x 0.74 x 1.37 x 1.09 x 0.71 x
EV / Revenue 3.55 x 2.06 x 1.65 x 1.37 x 2.39 x 1.5 x
EV / EBITDA 13.1 x 5.74 x 3.88 x 8.61 x 9.83 x 4.48 x
EV / FCF -9.13 x -10.8 x -19.9 x - 45.2 x 11.3 x
FCF Yield -11% -9.24% -5.01% - 2.21% 8.86%
Price to Book - - - - - -
Nbr of stocks (in thousands) 115,153 136,713 148,963 217,484 245,451 -
Reference price 3 0.9900 0.6400 0.2400 0.2900 0.2400 0.2400
Announcement Date 15/04/21 20/04/22 22/03/23 10/05/24 - -
1CAD in Million2USD in Million3CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 25.19 37.24 35.41 34.81 39.7 61.36
EBITDA 1 6.813 13.39 15.12 5.528 9.661 20.55
EBIT 4.686 - - -7.843 - -
Operating Margin 18.6% - - -22.53% - -
Earnings before Tax (EBT) 2.639 - - - - -
Net income 2.125 - - - - -
Net margin 8.43% - - - - -
EPS 0.0251 - - 0.0410 - -
Free Cash Flow 1 -9.803 -7.102 -2.938 - 2.101 8.17
FCF margin -38.91% -19.07% -8.3% - 5.29% 13.31%
FCF Conversion (EBITDA) - - - - 21.75% 39.76%
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 15/04/21 20/04/22 22/03/23 10/05/24 - -
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 9.308 10.79 8.766 7.673 8.181 9.111 9.187 8.099 8.415 8.39 8.729 10 12
EBITDA 1 3.37 3.887 4.847 3.279 3.181 2.931 1.049 1.077 0.5506 1.957 1.7 2.5 3.45
EBIT - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - -
Net income - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - -
EPS - - - - - - - -0.0136 0.0546 - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 20/04/22 30/05/22 24/08/22 17/11/22 22/03/23 25/05/23 23/08/23 28/11/23 10/05/24 29/05/24 - - -
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt 1 - 7.64 32.2 - 51.7 48.9
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) - 0.57 x 2.131 x - 5.351 x 2.38 x
Free Cash Flow 1 -9.8 -7.1 -2.94 - 2.1 8.17
ROE (net income / shareholders' equity) 6.86% 12.8% 13.6% - - -
ROA (Net income/ Total Assets) 4.51% 8.82% 8.75% - - -
Assets 47.12 - - - - -
Book Value Per Share - - - - - -
Cash Flow per Share - 0.1000 0.0600 - - -
Capex 1 4.06 18.8 8.86 - 5.52 2.43
Capex / Sales 16.13% 50.43% 25.02% - 13.91% 3.96%
Announcement Date 15/04/21 20/04/22 22/03/23 10/05/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.24 CAD
Average target price
0.72 CAD
Spread / Average Target
+200.00%
Consensus
  1. Stock Market
  2. Equities
  3. VEXT Stock
  4. Financials Vext Science, Inc.